+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Ezetimibe: Use, costs, and adverse events in Australia



Ezetimibe: Use, costs, and adverse events in Australia



Cardiovascular Therapeutics 35(1): 40-46



To analyze the subsidized use and reported adverse events of ezetimibe, used to lower cholesterol, in Australia over the 11 years following its inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2004. Pharmacoepidemiological analysis of dispensed prescriptions from Medicare Australia. Adverse event data were obtained from the Therapeutic Goods Administration. Use was measured by the defined daily dose (DDD) per 1000 population per day for each calendar year. Adverse events were counted by organ class system. Total ezetimibe use rose to 8.46 DDD/1000 population/d in the 11 years to 2015. Ezetimibe as a sole active ingredient was the most commonly dispensed formulation followed by the two combination products containing ezetimibe and 40 mg or 80 mg simvastatin. The average yearly increase in utilization was 19% with a 24% annual increase in costs to government (2006-2015) to $169.0 million in 2015. There were substantial differences in ezetimibe use between states, with no relationship to deaths from ischaemic heart disease (IHD) in each jurisdiction. The major reported adverse events were musculoskeletal and connective tissue disorders and gastrointestinal disorders. Ezetimibe use has increased rapidly in Australia since receiving public subsidy. Although the indications for subsidy are very restricted, there appears to have been widespread use, not explained by differential geographical IHD death rates. Latest guidelines still question the value of ezetimibe, so further discussion about whether the public spending on this medication for any potential improvement in population health outcomes is justified.

(PDF emailed within 0-6 h: $19.90)

Accession: 057851745

Download citation: RISBibTeXText

PMID: 27860332

DOI: 10.1111/1755-5922.12236


Related references

The costs and adverse events associated with hospitalization of patients with spinal cord injury in Victoria, Australia. Spine 35(7): 796-802, 2010

The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 277(4): 307-311, 1997

Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. PharmacoTherapy 32(3): 234-243, 2012

Simvastatin-ezetimibe combination therapy is associated with a lower rate of major adverse cardiac events in type 2 diabetics than high potency statins alone: A population-based dynamic cohort study. International Journal of Cardiology 190: 20-25, 2016

Costs of adverse events in intensive care units. Critical Care Medicine 35(11): 2479-2483, 2007

The costs of adverse drug events in community hospitals. Joint Commission Journal on Quality and Patient Safety 38(3): 120-126, 2012

Hospital costs associated with adverse events in gynecological oncology. Gynecologic Oncology 121(1): 70-75, 2011

Costs of Adverse Drug Events: Systematic Review. Value in Health 18(7): A517, 2015

Counting the costs of drug-related adverse events. Pharmacoeconomics 15(5): 445-458, 1999

Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia. Human Vaccines and Immunotherapeutics 11(7): 1828-1835, 2016

Direct medical costs of adverse events in Dutch hospitals. Bmc Health Services Research 9: 27, 2009

Focus on adverse drug events to reduce LOS, slash costs. Capitation Rates & Data 6(6): 65-67, 2001

Costs of serious adverse events in a community teaching hospital, in Mexico. Cirugia Y Cirujanos 83(3): 211-216, 2016

Software helps reduce adverse events and determine financial costs. Report on Medical Guidelines and Outcomes Research 12(9): 5-7, 2002

The costs and savings associated with prevention of adverse events by critical care nurses. Journal of Critical Care 24(3): 471.E1-7, 2009